Loading...

Barbara Mason

TitleAdjunct Professor
InstitutionUniversity of California San Diego
DepartmentPsychiatry
Address9500 Gilman Drive #0603
La Jolla CA 92093
vCardDownload vCard

    Collapse Research 
    Collapse Research Activities and Funding
    Proof-of-Concept Human Laboratory Testing of Novel Drug Candidates Identified by INIA-NeuroImmune
    NIH/NIAAA U01AA025476Feb 1, 2017 - Jan 31, 2022
    Role: Principal Investigator
    Recent Frontiers and Advances in Drug Addiction (IDARS Conference)
    NIH/NIDA R13DA040432Aug 1, 2015 - Jul 31, 2016
    Role: Principal Investigator
    Glucocorticoid Antagonist Treatment of Alcohol Use Disorder
    NIH/NIAAA R01AA023152Sep 1, 2014 - Jun 30, 2019
    Role: Principal Investigator
    Pharmacological Treatment of Cannabis Withdrawal and Dependence
    NIH/NIDA R01DA030988Sep 30, 2010 - Jan 31, 2016
    Role: Principal Investigator
    Gabapentin Treatment of Cannabis Dependence
    NIH/NIDA R01DA026758Jul 15, 2009 - May 31, 2014
    Role: Principal Investigator
    TRANSLATIONAL CTR ON THE CLINICAL NEUROBIOL OF CANNABIS ADDICTION
    NIH/NIDA P20DA024194Sep 30, 2007 - Jun 30, 2012
    Role: Principal Investigator
    Gabapentin for Cannabis Withdrawal and Use
    NIH/NIDA R21DA020766May 1, 2006 - Oct 30, 2008
    Role: Principal Investigator
    Duloxetine versus Pregabalin for Treatment of Alcohol Dependence
    NIH/NIAAA R37AA014028Mar 1, 2003 - Aug 31, 2014
    Role: Principal Investigator
    Medication Development for Protracted Abstinence in Alcoholism
    NIH/NIAAA R01AA012602Sep 25, 1999 - Jun 30, 2016
    Role: Principal Investigator
    BEHAVIORAL/PHARMACOLOGIC TREATMENT OF ALCOHOLISM
    NIH/NIAAA U10AA011727Sep 30, 1997 - Aug 31, 2005
    Role: Co-Principal Investigator
    NALMEFENE IN NICOTINE AND ALCOHOL DEPENDENCE
    NIH/NIAAA R01AA011210Sep 29, 1996 - May 31, 2005
    Role: Principal Investigator
    NALMEFENE MAINTENANCE TREATMENT OF ALCOHOLISM
    NIH/NIAAA R01AA010518Apr 1, 1995 - Mar 31, 2002
    Role: Principal Investigator
    NALMEFENE MODIFICATION OF ALCOHOLISM
    NIH/NIAAA R01AA009560Sep 30, 1992 - Aug 31, 1996
    Role: Principal Investigator
    DESIPRAMINE METABOLISM IN RECOVERING ALCOHOLICS
    NIH/NIAAA R01AA008111Jan 1, 1990 - Dec 31, 1993
    Role: Principal Investigator
    LONGTERM ANTIDEPRESSANT TREATMENT OF ALCOHOLISM
    NIH/NIAAA R23AA006866Mar 1, 1987 - Feb 28, 1991
    Role: Principal Investigator
    CNS Effects of Alcohol: Cellular Neurobiology
    NIH/NIAAA P60AA006420Dec 1, 1983 - Dec 31, 2022
    Role: Principal Investigator

    Collapse Bibliographic 
    Collapse Publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Researchers can login to make corrections and additions, or contact us for help.
    List All   |   Timeline
    1. Mason BJ, Quello S, Shadan F. Gabapentin for the treatment of alcohol use disorder. Expert Opin Investig Drugs. 2018 Jan; 27(1):113-124. PMID: 29241365.
      View in: PubMed
    2. Mason BJ. Emerging pharmacotherapies for alcohol use disorder. Neuropharmacology. 2017 Aug 01; 122:244-253. PMID: 28454983.
      View in: PubMed
    3. Salaheddin K, Mason B. Identifying barriers to mental health help-seeking among young adults in the UK: a cross-sectional survey. Br J Gen Pract. 2016 Oct; 66(651):e686-92. PMID: 27688518.
      View in: PubMed
    4. Koob GF, Mason BJ. Existing and Future Drugs for the Treatment of the Dark Side of Addiction. Annu Rev Pharmacol Toxicol. 2016; 56:299-322. PMID: 26514207.
      View in: PubMed
    5. Vendruscolo LF, Estey D, Goodell V, Macshane LG, Logrip ML, Schlosburg JE, McGinn MA, Zamora-Martinez ER, Belanoff JK, Hunt HJ, Sanna PP, George O, Koob GF, Edwards S, Mason BJ. Glucocorticoid receptor antagonism decreases alcohol seeking in alcohol-dependent individuals. J Clin Invest. 2015 Aug 03; 125(8):3193-7. PMID: 26121746; PMCID: PMC4563748.
    6. Mason BJ. Acamprosate, alcoholism, and abstinence. J Clin Psychiatry. 2015 Feb; 76(2):e224-5. PMID: 25742214.
      View in: PubMed
    7. Perney P, Rigole H, Mason B, Dematteis M, Lehert P. Measuring sleep disturbances in patients with alcohol use disorders: a short questionnaire suitable for routine practice. J Addict Med. 2015 Jan-Feb; 9(1):25-30. PMID: 25629883.
      View in: PubMed
    8. Mason BJ, Goodell V, Shadan F. Gabapentin treatment for alcohol dependence--reply. JAMA Intern Med. 2014 Jul; 174(7):1201-2. PMID: 25003890.
      View in: PubMed
    9. Araos P, Pedraz M, Serrano A, Lucena M, Barrios V, García-Marchena N, Campos-Cloute R, Ruiz JJ, Romero P, Suárez J, Baixeras E, de la Torre R, Montesinos J, Guerri C, Rodríguez-Arias M, Miñarro J, Martínez-Riera R, Torrens M, Chowen JA, Argente J, Mason BJ, Pavón FJ, Rodríguez de Fonseca F. Plasma profile of pro-inflammatory cytokines and chemokines in cocaine users under outpatient treatment: influence of cocaine symptom severity and psychiatric co-morbidity. Addict Biol. 2015 Jul; 20(4):756-72. PMID: 24854157.
      View in: PubMed
    10. Mason BJ, Quello S, Goodell V, Shadan F, Kyle M, Begovic A. Gabapentin treatment for alcohol dependence: a randomized clinical trial. JAMA Intern Med. 2014 Jan; 174(1):70-7. PMID: 24190578; PMCID: PMC3920987.
    11. Mason BJ, Higley AE. A translational approach to novel medication development for protracted abstinence. Curr Top Behav Neurosci. 2013; 13:647-70. PMID: 22351425.
      View in: PubMed
    12. Mason BJ, Crean R, Goodell V, Light JM, Quello S, Shadan F, Buffkins K, Kyle M, Adusumalli M, Begovic A, Rao S. A proof-of-concept randomized controlled study of gabapentin: effects on cannabis use, withdrawal and executive function deficits in cannabis-dependent adults. Neuropsychopharmacology. 2012 Jun; 37(7):1689-98. PMID: 22373942; PMCID: PMC3358737.
    13. Perney P, Lehert P, Mason BJ. Sleep disturbance in alcoholism: proposal of a simple measurement, and results from a 24-week randomized controlled study of alcohol-dependent patients assessing acamprosate efficacy. Alcohol Alcohol. 2012 Mar-Apr; 47(2):133-9. PMID: 22218671.
      View in: PubMed
    14. Higley AE, Koob GF, Mason BJ. Treatment of alcohol dependence with drug antagonists of the stress response. Alcohol Res. 2012; 34(4):516-21. PMID: 23584117; PMCID: PMC3860394.
    15. Mason BJ, Lehert P. Acamprosate for alcohol dependence: a sex-specific meta-analysis based on individual patient data. Alcohol Clin Exp Res. 2012 Mar; 36(3):497-508. PMID: 21895717; PMCID: PMC3288465.
    16. Higley AE, Crane NA, Spadoni AD, Quello SB, Goodell V, Mason BJ. Craving in response to stress induction in a human laboratory paradigm predicts treatment outcome in alcohol-dependent individuals. Psychopharmacology (Berl). 2011 Nov; 218(1):121-9. PMID: 21607563; PMCID: PMC3191263.
    17. Crean RD, Tapert SF, Minassian A, Macdonald K, Crane NA, Mason BJ. Effects of chronic, heavy cannabis use on executive functions. J Addict Med. 2011 Mar; 5(1):9-15. PMID: 21643485; PMCID: PMC3106308.
    18. Crean RD, Crane NA, Mason BJ. An evidence based review of acute and long-term effects of cannabis use on executive cognitive functions. J Addict Med. 2011 Mar; 5(1):1-8. PMID: 21321675; PMCID: PMC3037578.
    19. Mason BJ, Heyser CJ. Acamprosate: a prototypic neuromodulator in the treatment of alcohol dependence. CNS Neurol Disord Drug Targets. 2010 Mar; 9(1):23-32. PMID: 20201812; PMCID: PMC2853976.
    20. Mason BJ, Lehert P. The effects of current subsyndromal psychiatric symptoms or past psychopathology on alcohol dependence treatment outcomes and acamprosate efficacy. Am J Addict. 2010 Mar-Apr; 19(2):147-54. PMID: 20163387.
      View in: PubMed
    21. Mason BJ, Heyser CJ. The neurobiology, clinical efficacy and safety of acamprosate in the treatment of alcohol dependence. Expert Opin Drug Saf. 2010 Jan; 9(1):177-88. PMID: 20021295.
      View in: PubMed
    22. Reid IR, Ames R, Mason B, Bolland MJ, Bacon CJ, Reid HE, Kyle C, Gamble GD, Grey A, Horne A. Effects of calcium supplementation on lipids, blood pressure, and body composition in healthy older men: a randomized controlled trial. Am J Clin Nutr. 2010 Jan; 91(1):131-9. PMID: 19906800.
      View in: PubMed
    23. Mason BJ, Shaham Y, Weiss F, Le AD. Stress, alcohol craving, and relapse risk: mechanisms and viable treatment targets. Alcohol. 2009 Nov; 43(7):541-3. PMID: 19913197; PMCID: PMC2805701.
    24. Mason BJ, Lehert P. Effects of nicotine and illicit substance use on alcoholism treatment outcomes and acamprosate efficacy. J Addict Med. 2009 Sep; 3(3):164-71. PMID: 21769013.
      View in: PubMed
    25. Koob GF, Kenneth Lloyd G, Mason BJ. Development of pharmacotherapies for drug addiction: a Rosetta stone approach. Nat Rev Drug Discov. 2009 Jun; 8(6):500-15. PMID: 19483710; PMCID: PMC2760328.
    26. Mason BJ, Light JM, Williams LD, Drobes DJ. Proof-of-concept human laboratory study for protracted abstinence in alcohol dependence: effects of gabapentin. Addict Biol. 2009 Jan; 14(1):73-83. PMID: 18855801; PMCID: PMC2758315.
    27. Mason BJ, Light JM, Escher T, Drobes DJ. Effect of positive and negative affective stimuli and beverage cues on measures of craving in non treatment-seeking alcoholics. Psychopharmacology (Berl). 2008 Sep; 200(1):141-50. PMID: 18604601; PMCID: PMC2758314.
    28. Mason BJ, Crean R. Acamprosate in the treatment of alcohol dependence: clinical and economic considerations. Expert Rev Neurother. 2007 Nov; 7(11):1465-77. PMID: 17997696.
      View in: PubMed
    29. Anton RF, O'Malley SS, Ciraulo DA, Cisler RA, Couper D, Donovan DM, Gastfriend DR, Hosking JD, Johnson BA, LoCastro JS, Longabaugh R, Mason BJ, Mattson ME, Miller WR, Pettinati HM, Randall CL, Swift R, Weiss RD, Williams LD, Zweben A. Combined pharmacotherapies and behavioral interventions for alcohol dependence: the COMBINE study: a randomized controlled trial. JAMA. 2006 May 03; 295(17):2003-17. PMID: 16670409.
      View in: PubMed
    30. Mason BJ, Goodman AM, Chabac S, Lehert P. Effect of oral acamprosate on abstinence in patients with alcohol dependence in a double-blind, placebo-controlled trial: the role of patient motivation. J Psychiatr Res. 2006 Aug; 40(5):383-93. PMID: 16546214.
      View in: PubMed
    31. Johnson BA, Koob GF, Schuckit MA, Mason BJ, Ait-Daoud N. Understanding and treating alcohol dependence. Alcohol Clin Exp Res. 2006 Mar; 30(3):567-84. PMID: 16499499.
      View in: PubMed
    32. Kranzler HR, Mueller T, Cornelius J, Pettinati HM, Moak D, Martin PR, Anthenelli R, Brower KJ, O'Malley S, Mason BJ, Hasin D, Keller M. Sertraline treatment of co-occurring alcohol dependence and major depression. J Clin Psychopharmacol. 2006 Feb; 26(1):13-20. PMID: 16415699.
      View in: PubMed
    33. Mason BJ. Acamprosate in the treatment of alcohol dependence. Expert Opin Pharmacother. 2005 Oct; 6(12):2103-15. PMID: 16197362.
      View in: PubMed
    34. Mason BJ. Rationale for combining acamprosate and naltrexone for treating alcohol dependence. J Stud Alcohol Suppl. 2005 Jul; (15):148-56; discussion 140. PMID: 16223066.
      View in: PubMed
    35. O'Malley SS, Martin DJ, Hosking JD, Mason BJ. How pilot studies improve large-scale clinical trials: lessons learned from the COMBINE Study. J Stud Alcohol Suppl. 2005 Jul; (15):66-71; discussion 65. PMID: 16223058.
      View in: PubMed
    36. Reid IR, Horne A, Mason B, Ames R, Bava U, Gamble GD. Effects of calcium supplementation on body weight and blood pressure in normal older women: a randomized controlled trial. J Clin Endocrinol Metab. 2005 Jul; 90(7):3824-9. PMID: 15827103.
      View in: PubMed
    37. Mason BJ. Acamprosate and naltrexone treatment for alcohol dependence: an evidence-based risk-benefits assessment. Eur Neuropsychopharmacol. 2003 Dec; 13(6):469-75. PMID: 14636963.
      View in: PubMed
    38. Mason BJ. Acamprosate. Recent Dev Alcohol. 2003; 16:203-15. PMID: 12638639.
      View in: PubMed
    39. Mason BJ, Goodman AM, Dixon RM, Hameed MH, Hulot T, Wesnes K, Hunter JA, Boyeson MG. A pharmacokinetic and pharmacodynamic drug interaction study of acamprosate and naltrexone. Neuropsychopharmacology. 2002 Oct; 27(4):596-606. PMID: 12377396.
      View in: PubMed
    40. Xie S, Suckow RF, Mason BJ, Allen D, Cooper TB. Rapid and sensitive determination of nalmefene in human plasma by gas chromatography-mass spectrometry. J Chromatogr B Analyt Technol Biomed Life Sci. 2002 Jun 25; 773(2):143-9. PMID: 12031840.
      View in: PubMed
    41. Koob GF, Mason BJ, De Witte P, Littleton J, Siggins GR. Potential neuroprotective effects of acamprosate. Alcohol Clin Exp Res. 2002 Apr; 26(4):586-92. PMID: 11981137.
      View in: PubMed
    Barbara's Networks
    Concepts
    Derived automatically from this person's publications.
    _
    Co-Authors
    People in Profiles who have published with this person.
    _
    Related Authors
    People who share related concepts with this person.
    _